Vaccitech
Vaccitech is a spin-out company from the University of Oxford's Jenner institute, one of the oldest and most renowned vaccine research centres in the world.
The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company's protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results.
Contact Vaccitech via their website
News archive
30/04/2010 Vaccitech Announces Oxford COVID-19 vaccine begins human trial...more
24/04/2020 Vaccitech and University of Oxford announce Covid-19 agreement with Astrazenca...more
31/01/2020 Phase 2 Clinical Results for Vaccitech’s Influenza A Vaccine...more
20/12/2019 Vaccitech reports New Saudi MERS vaccine clinical trial...more
18/12/2019 Vaccitech and Cancer Research UK collaborate on first-line NSCLC therapy...more
25/11/2019 Vaccitech update on Phase 2 Universal Influenza studies...more
29/10/2019 Vaccitech to present clinical development of Universal Influenza A Vaccine...more
27/08/2019 Vaccitech Appoints Bill Enright as New Chief Executive Officer...more
15/07/2019 Vaccitech appoints Mariem Charafeddine as Chief Medical Officer...more
05/06/2019 Vaccitech Universal flu vaccine passes Phase 2b milestones...more
15/05/2019 ProBioGen and Vaccitech Sign Technology Platform License Agreement...more
04/03/2019 Vaccitech Awarded BARDA contract for Phase II flu trial...more
28/02/2019 Vaccitech joins the BioPartner programme...more
